|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-11-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Platinum-containing two-drug combinations improve survival and cancer-related symptoms in patients with advanced non-small-cell lung cancer (NSCLC). However, survival benefit is modest and platinum-containing regimens cause substantial toxic effects. We did a prospective randomised open-label phase III study to compare an experimental platinum-free, triplet, sequential regimen of vinorelbine plus gemcitabine followed by docetaxel with the standard platinum-containing, doublet regimen paclitaxel plus carboplatin in patients with advanced NSCLC.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine,
http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1474-5488
|
|
pubmed:author |
pubmed-author:FujitaYukaY,
pubmed-author:FukushimaMasanoriM,
pubmed-author:FuruseKiyoyukiK,
pubmed-author:Japan Multi-National Trial Organisation,
pubmed-author:KawaharaMasaakiM,
pubmed-author:KomutaKiyoshiK,
pubmed-author:KubotaKaoruK,
pubmed-author:MinatoKoichiK,
pubmed-author:NishiwakiYutakaY,
pubmed-author:OgawaraMitsumasaM,
pubmed-author:TeramukaiSatoshiS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1135-42
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19013107-Adult,
pubmed-meshheading:19013107-Aged,
pubmed-meshheading:19013107-Aged, 80 and over,
pubmed-meshheading:19013107-Antimetabolites, Antineoplastic,
pubmed-meshheading:19013107-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:19013107-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19013107-Carboplatin,
pubmed-meshheading:19013107-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19013107-Deoxycytidine,
pubmed-meshheading:19013107-Disease-Free Survival,
pubmed-meshheading:19013107-Female,
pubmed-meshheading:19013107-Humans,
pubmed-meshheading:19013107-Kaplan-Meier Estimate,
pubmed-meshheading:19013107-Lung Neoplasms,
pubmed-meshheading:19013107-Male,
pubmed-meshheading:19013107-Middle Aged,
pubmed-meshheading:19013107-Neoplasm Staging,
pubmed-meshheading:19013107-Paclitaxel,
pubmed-meshheading:19013107-Smoking,
pubmed-meshheading:19013107-Taxoids,
pubmed-meshheading:19013107-Vinblastine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
|
|
pubmed:affiliation |
National Cancer Centre Hospital East, Kashiwa, Chiba, Japan.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
